Cancer
Breast cancer in Shijiazhuang
石家庄 乳腺癌
3 hospitals in Shijiazhuang
Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shijiazhuang may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 132 papers led
- 29 papers ledNo open trial led
- 19 papers ledNo open trial led
Breast cancer in every city Shijiazhuang on the disease page, with the national map
open trials on breast cancer with a hospital in Shijiazhuang
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shijiazhuang as lead sponsor or study site. 9 of them are led by a hospital in Shijiazhuang. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingReal-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT06993506
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou
- RecruitingA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07347600
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou
- RecruitingBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07492641
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingSMP-656 for HER2-Positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07726342
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07876557
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou
- RecruitingA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06891833
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07008976
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou
- RecruitingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07043725
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou
- RecruitingJS207 Combination Therapy in Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07045311
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07047365
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07062965
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an
- RecruitingLevel I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07469267
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan
- RecruitingDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07492394
Age 18 years to 75 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingEfficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT05578053
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT07635342
Age 18 years to 65 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05696626
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05860465
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan
- RecruitingEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05872347
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05894239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan
- RecruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06079983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingDalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06107673
Age 18 years to 75 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingChemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2022-03
- Posted
- Registry
- NCT05525767
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingEffect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-06
- Posted
- Registry
- NCT04790305
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
- RecruitingClinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer
- Phase
- Not given
- Started
- 2020-11
- Posted
- Registry
- NCT06375798
Age 55 years to Not stated; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingNab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
- Phase
- Phase 2
- Started
- 2019-11
- Posted
- Registry
- NCT04138719
Age 18 years to 70 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingNab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2019-11
- Posted
- Registry
- NCT04159142
Age 18 years to 70 years; women only (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingNeoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07528898
Age 18 years to 70 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingCulmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07745257
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou
- Not yet recruitingEvaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07246317
Age 18 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 4 listed hospitals as study sitesGuangzhou, Luoyang, Shijiazhuang, Tianjin
- Not yet recruitingClinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
- Phase
- Phase 4
- Started
- 2023-10
- Posted
- Registry
- NCT05860907
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Shijiazhuang
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Hebei University河北大学附属医院 | none | 4 | none | 5 | 23 | none | 19 | 11 | none | none | none | 1 | none | none | none | 4 | none | none | none | 2 | 1 | none | none | none | none | none | none | none | none | none | none | 9 | 4 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital, Army Medical University陆军军医大学士官学校附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Bethune International Peace Hospital中国人民解放军白求恩国际和平医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | |
| Chest Hospital河北省胸科医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Hospital of Hebei Medical University河北医科大学第一医院 | none | 1 | 8 | 4 | 17 | 5 | none | none | none | none | none | none | 1 | none | none | none | none | 0 | none | 5 | none | none | none | none | none | none | none | none | none | none | none | 16 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fourth Hospital of Hebei Medical University河北医科大学第四医院 | none | 12311 open | 201 open | 1047 open | 1375 open | 91 open | 1329 open | none | 1 | none | none | 6 | 7 | none | none | 4 | none | none | 2 | 25 | none | none | none | none | none | none | none | 2 | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hebei Children's Hospital河北省儿童医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hebei General Hospital河北省人民医院 | none | 5 | none | 101 open | 51 | 8 | 29 | none | none | none | none | 0 | none | 1 | none | none | none | none | none | 9 | none | 1 | none | none | none | 2 | none | none | none | none | none | 10 | 7 | none | 1 | 1 | none | 1 | none | none | none | none | none | 1 | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hebei Province Hospital河北省中医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Hospital of Hebei Medical University河北医科大学第二医院 | none | 5 | none | 23 | 42 | 10 | none | 54 | none | none | none | 0 | 1 | 6 | 0 | 3 | none | none | 1 | 8 | none | 0 | none | 0 | none | 16 | none | none | 2 | none | none | 17 | 5 | none | 1 | none | none | 3 | none | 19 | 0 | 2 | none | 4 | 0 | none | 2 | 0 | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | |
| Shijiazhuang Fifth Hospital石家庄市第五医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | |
| Shijiazhuang People's Hospital石家庄市第一医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shijiazhuang Ping'an Hospital石家庄平安医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Hospital of Hebei Medical University河北医科大学第三医院 | none | none | 22 | none | none | none | none | none | none | none | none | 8 | none | 1 | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | 6 | none | 12 | none | none | none | 0 | none | 0 | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Shijiazhuang.
- Oesophageal squamous cell carcinoma 12311 open
- Hepatocellular carcinoma 201 open
- Stomach cancer 1047 open
- Lung cancer 1375 open
- Pancreatic cancer 91 open
- Breast cancer 1329 open
- Hepatoblastoma 1
- Osteosarcoma 6
- Gastrointestinal stromal tumour 7
- Multiple myeloma 4
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 25
- Myasthenia gravis 2
- Coronary heart disease 6
- Behçet disease 0
- IgA nephropathy 1
- Oesophageal squamous cell carcinoma 5
- Stomach cancer 101 open
- Lung cancer 51
- Pancreatic cancer 8
- Breast cancer 29
- Osteosarcoma 0
- Neuroblastoma 1
- Lymphoma 9
- Haemophilia A 1
- Neuromyelitis optica spectrum disorder 2
- Coronary heart disease 10
- Congenital heart disease 7
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 1
- Duchenne muscular dystrophy 1
- Behçet disease 0
- IgA nephropathy 0
- Oesophageal squamous cell carcinoma 5
- Stomach cancer 23
- Lung cancer 42
- Pancreatic cancer 10
- Glioma 54
- Osteosarcoma 0
- Gastrointestinal stromal tumour 1
- Neuroblastoma 6
- Ewing sarcoma 0
- Multiple myeloma 3
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 8
- Haemophilia A 0
- Thrombotic thrombocytopenic purpura 0
- Neuromyelitis optica spectrum disorder 16
- Moyamoya disease 2
- Coronary heart disease 17
- Congenital heart disease 5
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 3
- Amyotrophic lateral sclerosis 19
- Spinal muscular atrophy 0
- Fabry disease 2
- Duchenne muscular dystrophy 4
- Behçet disease 0
- IgA nephropathy 2
- Gaucher disease 0
- Primary biliary cholangitis 1
- Hirschsprung disease 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for breast cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shijiazhuang on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.